From: The expanding Pandora’s toolbox of CD8+T cell: from transcriptional control to metabolic firing
anti-PD-1/PD-L1 | combinational therapy | cancer | Refs. |
---|---|---|---|
Pembrolizumab | Pemetrexed; carboplatin; paclitaxel; gemcitabine; cisplatin; 5-fuorouracil; trastuzumab; radiotherapy; Axitinib; Lenvatinib; PF-05082566 | Solid tumors; NSCLC; SCLC; TNBC; GC; | |
Nivolumab | 5-fuorouracil; oxaliplatin; capecitabine; oxaliplatin; ipilimumab; radiotherapy | NSCLC; SCLC; GC; colorectal cancer; Esophageal adenocarcinoma | |
Camrelizumab | Carboplatin; pemetrexed; gemcitabine; cisplatin; apatinib | Nasopharyngeal carcinoma; NSCLC; GC; HCC; SCLC; esophageal squamous cell carcinoma | |
Tislelizumab | Paclitaxel; carboplatin; platinum; pemetrexed; pamiparib | NSCLC | |
Atezolizumab | Bevacizumab; paclitaxel; carboplatin; etoposide; KY1044; alectinib; ipatasertib | NSCLC; SCLC; TNBC; HCC | |
Durvalumab | Etoposide; carboplatin; cisplatin; axitinib; radiotherapy | NSCLC; SCLC; RCC |